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OBJECTIVE—Cross-sectional studies found less microalbumin-
uria in type 2 diabetic patients with the Ala12 allele of the
peroxisome proliferator–activated receptor-2 (PPAR-2)
Pro12Ala polymorphism. We prospectively evaluated the associ-
ation between Pro12Ala polymorphism (rs1801282) and new-
onset microalbuminuria.
RESEARCH DESIGN AND METHODS—Pro12Ala polymor-
phism was genotyped by TaqMan-based assay in genomic DNA of
1,119 consenting patients from BErgamo NEphrologic DIabetic
Complications Trial (BENEDICT)—a prospective, randomized
trial evaluating ACE inhibition effect on new-onset microalbu-
minuria (albuminuria 20–200 g/min in at least two of three
consecutive overnight urine collections in two consecutive vis-
its) in hypertensive type 2 diabetes with albuminuria 20 g/min
at inclusion.
RESULTS—Baseline characteristics of Ala (Ala/Ala or Ala/
Pro) carriers and Pro/Pro homozygotes were similar, with a
nonsigniﬁcant trend to lower albuminuria (P  0.1107) in the
177 Ala carriers. Over a median (interquartile range) of 44.0
(17.1–51.9) months, 7 (4%) Ala carriers and 86 (9.1%) Pro/Pro
homozygotes developed microalbuminuria (hazard ratio [HR]
0.45 [95% CI 0.21–0.97]; P  0.042). Final albuminuria was
signiﬁcantly lower in Ala carriers than Pro/Pro homozygotes
(7.3  9.1 vs. 10.5  24.9 g/min, respectively), even after
adjustment for baseline albuminuria (P  0.048). Baseline and
follow-up blood pressure and metabolic control were similar
in both groups. Incidence of microalbuminuria was signiﬁ-
cantly decreased by ACE versus non-ACE inhibitor therapy in
Pro/Pro homozygotes (6.3 vs. 11.9%, respectively, HR 0.46
[0.29–0.72]; P  0.001).
CONCLUSIONS—In type 2 diabetes, the Ala allele protects
from worsening albuminuria and new-onset microalbuminuria,
and ACE inhibition blunts the excess risk of microalbuminuria
associated with the Pro/Pro genotype. Evaluating Pro12Ala poly-
morphism may help identifying patients at risk who may beneﬁt
the most from early renoprotective therapy. Diabetes 58:2920–
2929, 2009
S
ince the early 1980s, microalbuminuria—deﬁned
as a urinary albumin excretion rate (AER) be-
tween 20 and 200 g/min (or 30 and 300 mg/24 h)
in overnight (or daily) urine collections—has
been identiﬁed as a new recognized renal and cardiovas-
cular risk factor in both diabetic and nondiabetic subjects
(1–3). Although ﬁndings of several randomized clinical
trials and community-based cohort studies subsequently
converged to indicate that incremental increases in albu-
minuria even within the normal range already carry higher
risk of nephropathy or cardiovascular events (4–6), which
led to consider the possibility to abandon this term (7,8),
microalbuminuria continued to be used as a clear-cut
baseline or outcome variable for observational and inter-
vention studies (9,10). In particular, studies in type 2
diabetes used microalbuminuria as a surrogate end point
for diabetic nephropathy and related cardiovascular mor-
bidity and mortality (11–13).
This approach was justiﬁed by evidence that microalbu-
minuria is an independent predictor of progression to
overt proteinuria and eventual renal function loss, as well
as of cardiovascular morbidity and mortality in people
with diabetes (14). Thus, early identiﬁcation of subjects
expected to develop microalbuminuria is instrumental to
implement intervention strategies aimed at limiting the
excess renal and cardiovascular risk in this population
(13,15).
Microalbuminuria is often associated with metabolic
syndrome, a syndrome of insulin resistance, obesity, dys-
lipidemia, and increased renal and cardiovascular morbid-
ity. Data suggest that insulin resistance precedes and
probably contributes to the development of microalbumin-
uria in type 1 diabetic patients (16) and in nondiabetic
subjects (17). A cross-sectional study showed that in type
2 diabetic men, an increase in the homeostasis model
assessment index, a surrogate of insulin resistance, was
signiﬁcantly associated with an increased spot urine
albumin-to-creatinine ratio, taken as an indicator of mi-
croalbuminuria (18). Consistently, a case-control study
showed that the total-body glucose disposal rate, the
gold-standard marker of insulin sensitivity quantiﬁed by
means of a euglycemic-hyperinsulinemic clamp technique,
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microalbuminuria than in those with “normal” urinary
albumin excretion and demonstrated that more severe
insulin resistance was independently associated with an
excess of microalbuminuria in this population (19).
Although largely sustained by acquired factors such as
decreased physical activity and obesity, familial clustering
of insulin resistance suggests that genetic factors may also
contribute to reduced insulin sensitivity (20,21) and to the
associated excess risk of renal involvement. Indeed, both
insulin resistance (20,22–26) and the risk of developing
microalbuminuria (27) or macroalbuminuria (27,28) have
been linked, at least in part, to the peroxisome proliferator–
activated receptor- (PPAR-) gene. PPAR- is a nuclear
hormone receptor that exists in four isoforms. The
PPAR-2 isoform is a widely expressed ligand-activated
transcription factor and a member of the steroid receptor
superfamily (29), which is involved in lipid and glucose
metabolism, fatty acid transport, and cell differentiation
(30). Of interest, in several studies the Ala12 variant of the
Pro12Ala polymorphism (rs1801282) of the PPAR-2 iso-
form has been associated with less insulin resistance and
a reduced risk of both type 2 diabetes (20,24–26) and
microalbuminuria (27,28). All these studies, however,
were cross-sectional in nature, and the confounding effect
of a survival bias could not be deﬁnitely excluded. This
bias may be particularly relevant when, as in the above
studies, populations at increased mortality rate (such as
those with type 2 diabetes or metabolic syndrome) are
considered. This might also explain why the above ﬁnd-
ings were apparently conﬂicting with data from another
cross-sectional study failing to detect any signiﬁcant asso-
ciation between Ala12 variant and reduced risk of mi-
croalbuminuria in a Japanese series of type 2 diabetic
patients (31).
To address this issue, we took advantage of a large
cohort of patients included in the BErgamo NEphrologic
DIabetic Complications Trial (BENEDICT) and followed
them prospectively in the setting of a randomized, double-
blind, placebo-controlled design to assess whether an ACE
inhibitor (either alone or in combination with a nondihy-
dropyridine calcium-channel blocker) may prevent mi-
croalbuminuria in subjects with type 2 diabetes and
hypertension but no evidence of renal involvement at
inclusion (13). This trial offered the unique opportunity to
test the role of the PPAR-2 Pro12Ala polymorphism and
of its interaction, if any, with different intervention strat-
egies on the risk of developing microalbuminuria in this
patient population.
RESEARCH DESIGN AND METHODS
BENEDICT was a double-blind, randomized, placebo-controlled study aimed
to assess whether ACE inhibitors and nondihydropyridine calcium-channel
blockers, alone or in combination, prevent microalbuminuria in subjects
with type 2 diabetes, hypertension, and normal urinary albumin excretion at
baseline (13). Patients (n  1,204) were randomly allocated to at least 3-year
treatment with the ACE inhibitor trandolapril, the nondihydropyridine calcium-
channel blocker verapamil, the combination of verapamil plus trandolapril,
or placebo, added on background non–ACE-inhibiting therapy targeting
systolic/diastolic blood pressure 120/80 mmHg (13). Primary end point was
new-onset persistent microalbuminuria (urinary albumin excretion 20 g
and 200 g/min in at least two of three consecutive overnight urine
collections on two consecutive visits 2 months apart). Urinary albumin
excretion was measured on fresh urines at the coordinating center by
nephelometry (Beckman Array System; Beckman Coulter) at randomization
and every 6 months thereafter.
Trandolapril plus verapamil and trandolapril alone signiﬁcantly delayed the
onset of microalbuminuria by factors of 2.6 and 2.1, respectively, compared
with placebo (P  0.01 for both). The incidence of microalbuminuria was
reduced to a similar extent by both treatments, whereas verapamil had an
effect on the incidence of microalbuminuria that was similar to that of placebo
(12,13). Thus, patients were pooled in two cohorts according to their original
allocation to ACE or non-ACE inhibitor therapy regardless of concomitant
therapy with verapamil or placebo. Gene-by-treatment interactions were
tested according to ACE inhibitor therapy (yes or no).
The study protocol was approved by the local ethics committees, and only
samples from patients who provided written informed consent according to
the Helsinki Declaration guidelines were considered for genetic analyses. All
data were handled in respect of patient conﬁdentiality and anonymity.
Genotyping. Genomic DNA was extracted from peripheral blood leukocytes
by standard methods. Genotyping for Pro12Ala single nucleotide polymor-
phism (SNP; rs1801282) was performed using TaqMan Pre-Designed SNP
genotyping assay from Applied Biosystems (assay C_1129864_10; ABI, Foster
City, CA). TaqMan genotyping reactions were performed on ABI 7900HT
genetic analyzer following manufacturer’s instructions. Genotypes were
scored by analyzing data on both real-time as well as allele discrimination
assay platforms using SDS software provided by ABI. Genotyping success rate
was 99%. As a quality-control procedure, we double-genotyped a subset of
200 individuals (18% of the whole sample) using a different genotyping method
on the LightCycler 480 System (Roche Diagnostics, http://www.roche-applied-
science.com). This was a melting curve-based genotyping method using
ﬂuorescence-labeled hybridization probes (32). Primers and probes for geno-
typing Pro12Ala SNP on LightCycler 480 System were designed, synthesized,
and validated by TIB Molbiol (Genoa, Italy, http://www.tib-molbiol.com) using
the genomic sequence available from NCBI dbSNP for the rs1801282. Reac-
tions were performed using 1  LightCycler 480 Genotyping Master (catalog
no. 04 707 524 001; Roche Applied Science), 10 pmol of each primer (forward
5gCC CAg TCC TTT CTg TgT T 3 and reverse 5 gTC CCC AAT AgC CgT ATC
Tg 3, melting temperature 55°C), 4 pmol of each probe (Sensor HybProbe LC
Red 640-CCT TCA CTg ATA CAC TgT CTg CAA ACA TAT CAC-phosphate and
Anchor HybProbe TCT CCT ATT gAC CCA gAA AgC gAT-ﬂuorescein, melting
temperature 60°C and 64°C, respectively), and 50 ng of genomic DNA in a ﬁnal
volume of 20 l according to manufacturer’s instructions. The concordance
rate between the two genotyping methods was 100%.
Statistical analyses. Patients’ baseline characteristics according to PPAR-2
Pro12Ala polymorphism are reported as means  SD or frequencies and
percentages. P values refer to Mann-Whitney U test and Pearson 	
2 for
continuous and categorical variables, respectively. Time to onset of mi-
croalbuminuria was considered as the main end point. For patients who did
not reach the main end point, time was censored at the last follow-up visit.
Cox proportional hazards regression models were used, and results are
expressed as hazard ratios (HRs) and 95% CIs.
To test the effect of Pro12Ala polymorphism on outcome, three different
statistical models have been designed: the ﬁrst was a model adjusted only for
ACE inhibitor therapy (i.e., yes or no  0 or 1); in the second model, variables
that predicted microalbuminuria onset in the whole cohort, such as sex,
smoking status, and A1C, were added to ACE inhibitor therapy; in the third
model, baseline AER levels, which were slightly lower at study entry in Ala
carriers, were taken into account in addition to ACE inhibitor therapy and
baseline covariates. Between-groups comparison of AER at ﬁnal visit was
carried out by ANCOVA, adjusting for baseline measurement. Nonnormally
distributed covariates (namely, AER and triglycerides) were log transformed
before analysis. P values  0.05 were considered signiﬁcant. All the analyses
were performed using SAS Statistical Package Release 9.1 (SAS Institute,
Cary, NC).
RESULTS
Patient characteristics. Of the 1,204 BENEDICT pa-
tients, 1,119 consented to genomic DNA analyses. Of these
patients, 7 (0.6%) and 170 (15.2%) were homozygous and
heterozygous for the Ala12 allele, respectively, from now
Ala carriers, and 942 (84.2%) were homozygous for the
Pro12 allele, from now Pro/Pro homozygotes (Fig. 1).
Frequency of Ala carriers was comparable with that
previously reported in other white populations (25). The
proportion of the Pro12Ala genotypes did not signiﬁcantly
deviate from Hardy-Weinberg equilibrium (	
2  0.05; P 
0.82). Data from homozygous and heterozygous Ala carri-
ers were pooled and considered together for comparative
analyses with Pro/Pro homozygotes. Baseline characteris-
tics of the two groups were similar (Tables 1 and 2), with
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(Table 1), as well as the proportion of patients allocated to
ACE inhibitor therapy (yes or no) within each group
(Table 1). Baseline characteristics of patients who had
been randomized to ACE inhibitor therapy (yes or no)
within the two genotype groups were similar (Table 1).
Outcomes according to Pro12Ala genotypes. Over a
median (interquartile range) of 44 (17.1–51.9) months of
follow-up, 7 Ala carriers (4%) compared with 86 Pro/Pro
homozygotes (9.1%) developed persistent microalbuminuria
(	
2  4.35; P  0.037). The unadjusted HR for microalbu-
minuria in Ala carriers compared with Pro/Pro homozy-
gotes was 0.45 (95% CI 0.21–0.97) (P  0.042) (Fig. 2).
Blood pressure and A1C levels at baseline as well as
throughout the whole study period were similar in the two
genotype groups (Table 1 and Fig. 3, overall: upper and
lower panel, respectively). Conversely, in Ala carriers
compared with Pro/Pro homozygotes urinary AER in-
creased less during the observation period and was signif-
icantly lower at ﬁnal visit even after adjustment for
baseline albuminuria (ANCOVA, P  0.048) (Fig. 4).
In multivariable analyses, sex, smoking status, baseline
albuminuria, baseline and follow-up A1C, and follow-up
mean arterial pressure signiﬁcantly predicted incident
microalbuminuria in the whole BENEDICT sample (P 
0.001 for all considered covariates). Ala carriers compared
with Pro/Pro homozygotes showed a trend with lower
incidence of microalbuminuria even after adjusting for
sex, smoking status, and baseline A1C (HR 0.48 [95% CI
0.22–1.05]; P  0.065), but not after adjusting also for
baseline albuminuria (HR 0.64 [0.29–1.40]; P  0.263). The
difference in the cumulative incidence of events between
the two genotype groups was constant throughout the
whole observation period, and new cases of microalbu-
minuria were approximately 50% less in Ala compared
with Pro/Pro homozygotes at each considered time point
of the follow-up (proportionality test, P  0.85).
To assess whether the difference in the development of
microalbuminuria by Pro12Ala genotype was due to dif-
ference in blood pressure or glucose control, we evaluated
interactions between baseline/follow-up mean arterial
pressure or A1C and genotype on incidence of microalbu-
minuria. There were no signiﬁcant interactions in the
overall population. Furthermore, the distribution of con-
comitant treatments with glucose-, blood pressure–, and
lipid-lowering agents as well as of antiplatelet agents at
baseline and on follow-up was similar in the two genotype
groups (Table 2). The proportion of patients on two or
more antihypertensive medications was also similar in the
two groups. However, there were numerically more pa-
tients on diet alone and fewer patients on insulin alone
among Ala carriers than among Pro/Pro homozygotes at
baseline as well as throughout the follow-up period (Table
2). Patients prematurely leaving the study were compara-
ble in the two genotype groups (Fig. 1).
Patient outcomes according to Pro12Ala genotypes
and ACE inhibitor therapy. Among Ala carriers, 4 of the
91 patients on ACE inhibitor compared with 3 of the 86 on
non-ACE inhibitor therapy developed microalbuminuria.
Thus, in the two treatment groups the incidence of mi-
croalbuminuria (4.4 vs. 3.5%, respectively) was similar (HR
1.21 [95% CI 0.27–5.40]; P  0.805). Concomitant medica-
tions, systolic/diastolic blood pressure, and A1C at base-
line and on follow-up were similar in the two treatment
groups (Table 1 and Fig. 3, Ala carriers: upper and lower
panel, respectively).
1204 normoalbuminuric patients
randomized and followed in BENEDICT
1119 patients with genomic DNA analyses
85 patients not consenting to
genomic DNA analyses
177 Ala carriers
4 micro-albuminuric
87 normo-albuminuric
at study end
3 micro-albuminuric
83 normo-albuminuric
at study end
29 micro-albuminuric
435 normo-albuminuric
at study end
57 micro-albuminuric
421 normo-albuminuric
at study end
23 withdrew consent,
3 excluded for medical
or technical reasons,
2 lost to follow-up,
19 had adverse events,
1 died  
21 withdrew consent,
2 excluded for medical
or technical reasons,
2 lost to follow-up,
17 had adverse events,
0 died  
91 ACEi-YES 86 ACEi-NO
942 Pro/Pro homozygotes
464 ACEi-YES 478 ACEi-NO
102 withdrew consent,
12 excluded for medical
or technical reasons,
6 lost to follow-up,
53 had adverse events,
3 died  
119 withdrew consent,
13 excluded for medical
or technical reasons,
6 lost to follow-up,
60 had adverse events,
7 died  
FIG. 1. Schematic diagram of the study. ACEi, ACE inhibitor therapy.
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ACE inhibitor and 57 of the 478 on non-ACE inhibitor
therapy developed microalbuminuria (	
2  9.14; P 
0.003). Thus, the incidence of microalbuminuria (6.3 vs.
11.9%, respectively) was signiﬁcantly lower in those on
ACE than in those on non-ACE inhibitor therapy (unad-
justed HR 0.46 [95% CI 0.29–0.72], P  0.001; adjusted for
baseline characteristics including or not including albu-
minuria 0.44 [0.28–0.69], P  0.001). A1C was similar in
the two groups at baseline and follow-up. Systolic/dia-
stolic blood pressure was similar at baseline, but tended to
be lower in patients on ACE inhibitor therapy in the
follow-up period (Table 1 and Fig. 3, Pro/Pro homozy-
gotes: upper panel). On follow-up, a similar proportion of
patients was on concomitant treatment with antidiabetic,
lipid-lowering, and antiplatelet agents and blood pressure–
lowering medications, with the exception of sympatholytic
agents that were more frequently prescribed in the non-
ACE inhibitor treatment arm (Table 2). The incidence of
microalbuminuria was signiﬁcantly lower in Ala carriers
than in Pro/Pro homozygotes among subjects on non-ACE
inhibitor therapy (unadjusted HR 0.30 [0.09–0.95]; P 
0.041). The difference was marginally signiﬁcant after
adjusting for sex, smoking status, and baseline A1C (HR
0.33 [0.10–1.05]; P  0.061) but failed to achieve the
statistical signiﬁcance after adjusting also for baseline
albuminuria (HR 0.56 [0.17–1.82]; P  0.333). Among
subjects on ACE inhibitor therapy, the incidence of mi-
croalbuminuria was similar in the two genotype groups
(unadjusted HR 0.75 [0.26–2.12]; P  0.582). Altogether,
the rate of microalbuminuria in ACE inhibitor–treated
Pro/Pro homozygotes was similar to that of Ala carriers
considered as a whole regardless of therapy (Fig. 5).
The interaction between baseline A1C and genotype on
development of microalbuminuria was signiﬁcant (P 
0.035) in Pro/Pro homozygotes without ACE inhibitor
therapy, but not in those on ACE inhibition (P  0.64).
Baseline A1C was higher in Pro/Pro homozygotes pro-
gressing to microalbuminuria compared with those with
stable urinary albumin excretion among patients without
ACE inhibitor therapy (P  0.0001), but not in those on
ACE inhibition. No signiﬁcant interactions were observed
in Ala carriers.
There was no signiﬁcant interaction between follow-up
A1C or mean blood pressure and genotype on develop-
ment of microalbuminuria in any considered group.
DISCUSSION
The main ﬁnding of our present study is that in a large and
homogeneous cohort of hypertensive patients with type 2
diabetes and normal AER prospectively followed in the
setting of a randomized clinical trial, those who carried the
Ala12 allele of the Pro12Ala PPAR-2 polymorphism had a
signiﬁcantly lower incidence of persistent microalbumin-
uria compared with carriers of the wild-type Pro/Pro
genotype. Consistently, Ala carriers compared with Pro/
Pro homozygotes showed a slower increase in albuminuria
over time that eventually translated into a signiﬁcantly
lower urinary albumin excretion at ﬁnal visit. The two
genotype groups were very similar for all considered
parameters, including prevalence of well-recognized risk
factors for microalbuminuria such as male sex and smok-
ing habit. Even more important, A1C and blood pressure
control were similar at inclusion as well as throughout the
whole study period, ruling out any confounding effect of
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ered outcomes. The comparable distribution to ACE or
non-ACE inhibitor therapy within each group also ex-
cluded the possibility that time-dependent changes in
albuminuria could be affected by an unbalanced inhibition
of the renin-angiotensin system. Altogether, the above
ﬁndings can be taken to suggest that the Ala12 allele is
associated with an inborn protective effect against time-
associated worsening of albuminuria that explained the
trend to less albuminuria at inclusion as well as the
signiﬁcantly reduced incidence of microalbuminuria ob-
served throughout the approximately 4 years of follow-up.
Consistently, the cumulative incidence of microalbumin-
uria was 50% lower in Ala carriers than in Pro/Pro
homozygotes at any considered time point of the follow-
up, and the difference between the two genotype groups
was not appreciably affected by censoring all events
observed in the ﬁrst 6 months after inclusion. These
ﬁndings provide consistent evidence that the reduced
incidence of microalbuminuria in Ala carriers was only
partially explained by less albuminuria at baseline and
rather reﬂected a genuine protective effect of the Ala allele
against progression to microalbuminuria that was sus-
tained throughout the whole observation period.
To the best of our knowledge, this is the ﬁrst longitudinal
evidence of a (conceivably) causal association between
the PPAR-2 Pro12Ala polymorphism and microalbumin-
uria. All previous studies exploring such association were
cross-sectional in nature (27,28,31) and could not describe
time-dependent changes in albuminuria according to dif-
ferent genotypes. Among the strengths of our present
study was the rigorous deﬁnition of the entry criteria
(including the diagnosis of normoalbuminuria that was
established on the basis of a urinary AER 20 g/min in at
least two of three consecutive overnight urine collec-
tions), which allowed to identify a homogeneous popula-
tion of patients with type 2 diabetes, and the standardized
monitoring and treatment of included patients that was
based on the guidelines of the BENEDICT study protocol
(13). In particular, the diagnosis of new-onset persistent
microalbuminuria was established on the basis of a uri-
nary AER between 20 and 200 g/min in at least two of
three consecutive overnight urine collections conﬁrmed in
two consecutive visits 2 months apart, which allowed to
avoid the confounding effect of random ﬂuctuations of
albuminuria and intermittent microalbuminuria. The reli-
ability of urine collections was evaluated by measuring
urinary creatinine excretion, and when the creatinine
excretion was out of the expected ranges the sample was
discarded and the patient was invited to repeat the
collection.
Addressing the mechanisms explaining the reduced risk
of microalbuminuria in carriers of the PPAR2 Ala12 allele
was beyond the purposes of the present study. However,
more insulin sensitivity in Ala carriers might explain why,
at comparable metabolic control, these patients tended to
need less hypoglycemic agents or insulin than Pro/Pro
homozygotes at baseline as well as throughout the whole
observation period. Whether less insulin resistance might
have a role in the reduced risk of developing microalbu-
minuria in this population is a matter of speculation (23).
Of note, failure to detect a signiﬁcant interaction of
follow-up A1C (or mean blood pressure) and genotype on
microalbuminuria was likely explained by the optimized
metabolic and blood pressure control achieved during the
study in all considered groups. Conceivably, this leveled
out the independent effect of blood glucose and arterial
pressure on progression to the end point. This increased
the study power to detect a speciﬁc predictive value for
the Pro12Ala polymorphism in this population.
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FIG. 2. Kaplan-Meier curves for the percentages of Ala carriers or Pro/Pro homozygotes in subjects who developed persistent microalbuminuria
throughout the study period.
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compared with non-ACE inhibitor therapy halved the
incidence of microalbuminuria in Pro/Pro homozygotes
that had their rate of microalbuminuria decreased to the
rates observed in Ala12 carriers considered as a whole. On
the other hand, the incidence of events was so low in Ala
carriers that the analyses were not sufﬁciently powered to
test the treatment effect in this population. The signiﬁcant
interaction we found between baseline A1C and risk of
microalbuminuria in Pro/Pro homozygotes without ACE
inhibitor therapy might indicate that less effective meta-
bolic control might increase the rate of progression to
microalbuminuria in those subjects who are at increased
risk because of their genetic background. This interaction
was lost in Pro/Pro homozygotes on ACE inhibitor therapy
most likely because treatment reduced the incidence of
microalbuminuria in particular in those at increased risk
because of higher A1C at inclusion. Thus, the Pro/Pro
genotype might be associated with a genetic predisposi-
tion to microalbuminuria that manifests in those with less
effective metabolic control and is prevented by ACE
inhibitor therapy. Conversely, Ala carriers would be intrin-
sically protected.
Of note, different outcomes in considered groups are not
likely explained by differences in metabolic or blood
pressure control on follow-up because multivariable anal-
yses failed to detect any signiﬁcant interaction between
follow-up A1C (or mean blood pressure) and treatment
arm on microalbuminuria. More frequent use of sympatho-
lytic agents in patients on non-ACE inhibitor treatment did
not likely affect progression to microalbuminuria in this
population because these agents have not been reported to
worsen insulin sensitivity or albuminuria in people with
diabetes (33).
Whether amelioration of insulin resistance through in-
hibited angiotensin II production might have contributed
to limit microalbuminuria in Pro/Pro homozygotes on ACE
inhibitor therapy independently of glycemia (34) is worth
investigating.
Limitations. Our present data on treatment effect accord-
ing to different genotypes cannot be taken to conclude that
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that response to treatment is different in the two genotype
groups. Indeed, the genotype-by-treatment interaction
failed to achieve statistical signiﬁcance (P  0.222)—a
ﬁnding most likely explained by the small number of
events in Ala carriers that limited the power of compara-
tive analyses between patients on ACE or non-ACE inhib-
itor therapy in this subgroup. Moreover, data should be
taken with caution because they were generated from
exploratory analyses of a study that was not originally
powered to test the hypotheses under evaluation here. On
the other hand, the protective effect of ACE inhibitor
therapy against the development of microalbuminuria in
Pro/Pro homozygotes was clinically relevant and statisti-
cally signiﬁcant. These data were obtained from carefully
monitored patients in the setting of a prospective, con-
trolled clinical trial and were in harmony with previous
ﬁndings from cross-sectional studies in similar patient
populations (27,28). Thus, they appear to be sufﬁciently
robust and reliable even if they were not veriﬁed in an
independent external test set. Of note, baseline character-
istics of study patients were similar to those of patients
referred to the Diabetology Units of the BENEDICT net-
work who had been screened for study participation but
had not been included in the trial. This provides the
evidence that our ﬁndings can be generalized to the
average population of patients with type 2 diabetes, in
particular to those with arterial hypertension but still no
evidence of renal involvement.
In conclusion, our prospective study found that among
normoalbuminuric hypertensive patients with type 2 dia-
betes, PPAR-2 Ala carriers had a reduced rate of persis-
tent microalbuminuria. Pro/Pro homozygotes were at
increased risk of developing microalbuminuria but their
risk was appreciably reduced by ACE inhibitor therapy.
Thus, screening for the Pro12Ala PPAR-2 polymorphism
may help to identify patients at increased risk who may
beneﬁt the most from early ACE inhibitor therapy. Further
studies are needed to unravel whether protection from
microalbuminuria may translate into a reduced long-term
risk of renal and cardiovascular events in this population.
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APPENDIX
BENEDICT Study Organization: members of the
BENEDICT Study Organization were as follows (all in Italy
unless otherwise noted): principal investigator: G. Re-
muzzi (Bergamo); study coordinator: P. Ruggenenti (Ber-
gamo); coordinating center: Mario Negri Institute for
Pharmacological Research, Clinical Research Center for
Follow-up (Months)
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FIG. 5. Kaplan-Meier curves for the percentages of Pro/Pro homozygotes considered according to concomitant ACE inhibitor therapy (ACEi) (yes
or no) and of Ala carriers considered as a whole in subjects who developed persistent microalbuminuria throughout the study period.
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Pietro, Villa d’Alme `); C. Chiurchiu, F. Arnoldi, L. Mosconi,
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(Bergamo), G. Remuzzi (Bergamo), U.F. Legler (Ludwig-
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Nehrdich (Ludwigshafen, Germany), A. Nicolucci (S.
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gamo); safety committee: G.L. Bakris (Chicago, IL), R. Kay
(Shefﬁeld, U.K.), G.C. Viberti (London, U.K.).
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